| Description | TIBI is an ATP-competitive Rio1 inhibitor that acts in a similar manner to fungamycin and enhances the thermal stability of the enzyme. |
| Target activity | Rio1:0.05 μM (Ki), Rio1:0.09 μM |
| molecular weight | 621.72 |
| Molecular formula | C7H2I4N2 |
| CAS | 1196457-06-3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 30 mg/mL (48.25 mM), Sonication is recommended. |
| References | 1. Kubiński K, et al. Benzimidazole inhibitors of protein kinase CK2 potently inhibit the activity of atypical protein kinase RioMol Cell Biochem. 2017 Feb;426(1-2):195-203. 2. Buckert D, Cieslik M, Tibi R, Radermacher M, Rottbauer W, Bernhardt P. Cardiac magnetic resonance imaging derived quantification of myocardial ischemia and scar improves risk stratification and patient management in stable coronary artery disease. Cardiol J. 2017 Mar 29. doi: 10.5603/CJ.a2017.0036. [Epub ahead of print] PubMed PMID: 28353309. 3. Jurj A, Tomuleasa C, Tat TT, Berindan-Neagoe I, Vesa SV, Ionescu DC. Antiproliferative and Apoptotic Effects of Lidocaine on Human Hepatocarcinoma Cells. A preliminary study. J Gastrointestin Liver Dis. 2017 Mar;26(1):45-50. doi: 10.15403/jgld.2014.1121.261.juj. PubMed PMID: 28338113. 4. Shao Z, Al Tibi M, Wakim-Fleming J. Update on viral hepatitis in pregnancy. Cleve Clin J Med. 2017 Mar;84(3):202-206. doi: 10.3949/ccjm.84a.15139. Review. PubMed PMID: 28322675. |